Abstract
We have reported that vaccination of mice with leukemic cells transduced with CD154 and IL12 led to a significant protection and generation of cytotoxicity T lymphocytes (CTL) against leukemia cells. But, we obtained 30% of protection in therapeutic protocol with persistence of residual disease. So, it is necessary to improve this immune response. It's why we decided to compare the efficacy of IP10, IP10+CD154, IP10+IL12 gene transfer mediated antileukemic immunity in our aggressive murine model of acute leukemia, and to investigate how T and NK cells were affected by gene transfer and presence of residual disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
